AR115288A1 - Anticuerpos humanizados contra el psma - Google Patents

Anticuerpos humanizados contra el psma

Info

Publication number
AR115288A1
AR115288A1 ARP190102169A ARP190102169A AR115288A1 AR 115288 A1 AR115288 A1 AR 115288A1 AR P190102169 A ARP190102169 A AR P190102169A AR P190102169 A ARP190102169 A AR P190102169A AR 115288 A1 AR115288 A1 AR 115288A1
Authority
AR
Argentina
Prior art keywords
antibodies
antibodies against
humanized antibodies
against psma
fragments
Prior art date
Application number
ARP190102169A
Other languages
English (en)
Inventor
Dr Pahl Andreas Prof
Hechler Torsten Dr
Original Assignee
Heidelberg Pharma Res Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heidelberg Pharma Res Gmbh filed Critical Heidelberg Pharma Res Gmbh
Publication of AR115288A1 publication Critical patent/AR115288A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente solicitud se refiere a anticuerpos humanizados y/o desinmunizados, a fragmentos de anticuerpos o a derivados de anticuerpos que se unen al antígeno de membrana específico de la próstata (PSMA) y a métodos para utilizar dichos anticuerpos, fragmentos de anticuerpos o derivados de anticuerpos, en el tratamiento del cáncer de próstata y de otras enfermedades neoplásicas así como neurológicas.
ARP190102169A 2018-07-31 2019-07-31 Anticuerpos humanizados contra el psma AR115288A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18186591 2018-07-31

Publications (1)

Publication Number Publication Date
AR115288A1 true AR115288A1 (es) 2020-12-16

Family

ID=63259376

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102169A AR115288A1 (es) 2018-07-31 2019-07-31 Anticuerpos humanizados contra el psma

Country Status (26)

Country Link
US (1) US11976131B2 (es)
EP (1) EP3830132B1 (es)
JP (1) JP7586399B2 (es)
KR (1) KR102927925B1 (es)
CN (1) CN112533956B (es)
AR (1) AR115288A1 (es)
AU (1) AU2019312801B2 (es)
BR (1) BR112021001237A2 (es)
CA (1) CA3104800A1 (es)
CL (1) CL2021000146A1 (es)
CO (1) CO2021000386A2 (es)
DK (1) DK3830132T5 (es)
ES (1) ES2934963T3 (es)
FI (1) FI3830132T3 (es)
HR (1) HRP20230115T1 (es)
HU (1) HUE061078T2 (es)
IL (1) IL279823B2 (es)
LT (1) LT3830132T (es)
MX (1) MX2021000783A (es)
PL (1) PL3830132T3 (es)
PT (1) PT3830132T (es)
RS (1) RS63943B1 (es)
SG (1) SG11202100607RA (es)
SI (1) SI3830132T1 (es)
WO (1) WO2020025564A1 (es)
ZA (1) ZA202008095B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107427566B (zh) * 2014-12-01 2021-08-17 宾夕法尼亚大学理事会 Dna抗体构建体及其使用方法
SG11202110287QA (en) 2019-04-24 2021-10-28 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
MX2023005192A (es) 2020-11-04 2023-05-15 Heidelberg Pharma Res Gmbh Composicion que comprende una combinacion de inhibidor de punto de control inmunitario y conjugado de anticuerpo-amatoxina para uso en la terapia del cancer.
EP4392454A4 (en) * 2021-08-27 2025-10-15 Janssen Biotech Inc ANTI-PSMA ANTIBODIES AND THEIR USES
US20230355792A1 (en) 2022-04-07 2023-11-09 Heidelberg Pharma Research Gmbh Methods of improving the therapeutic index
JP2026507228A (ja) 2023-03-03 2026-02-27 アーセナル バイオサイエンシズ インコーポレイテッド Ｐｓｍａ及びｃａ９を標的とするシステム
EP4680285A1 (en) 2023-03-13 2026-01-21 Heidelberg Pharma Research GmbH Subcutaneously administered antibody-drug conjugates for use in cancer treatment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE318147T1 (de) 1996-03-25 2006-03-15 Medarex Inc Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
DE60031279T2 (de) 1999-07-29 2007-05-16 Medarex, Inc. Humane monoklonale antikörper gegen prostata spezifisches membranantigen
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
EP1726650A1 (en) * 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
DE202007018529U1 (de) 2007-07-07 2008-12-04 Chamalow S.A. Implantierbarer Funkfrequenzdefibrillator R.F.
EP3106468A1 (en) 2008-10-01 2016-12-21 Amgen Research (Munich) GmbH Cross-species-specific psmaxcd3 bispecific single chain antibody
WO2010045340A1 (en) * 2008-10-14 2010-04-22 Centocor Ortho Biotech Inc. Methods of humanizing and affinity-maturing antibodies
TWI653333B (zh) * 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
EP3587454A1 (en) * 2018-06-27 2020-01-01 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors that bind to prostate specific membrane antigen

Also Published As

Publication number Publication date
KR102927925B1 (ko) 2026-02-13
IL279823A (en) 2021-03-01
CN112533956A (zh) 2021-03-19
KR20210039389A (ko) 2021-04-09
US20230250189A1 (en) 2023-08-10
JP2021532778A (ja) 2021-12-02
HUE061078T2 (hu) 2023-05-28
MX2021000783A (es) 2021-03-31
ZA202008095B (en) 2023-09-27
DK3830132T5 (da) 2024-08-19
PL3830132T3 (pl) 2023-04-17
EP3830132A1 (en) 2021-06-09
CO2021000386A2 (es) 2021-07-19
EP3830132B1 (en) 2022-11-23
PT3830132T (pt) 2023-01-05
SI3830132T1 (sl) 2023-03-31
AU2019312801B2 (en) 2025-09-11
DK3830132T3 (da) 2023-01-02
US11976131B2 (en) 2024-05-07
IL279823B2 (en) 2026-02-01
AU2019312801A1 (en) 2021-03-11
ES2934963T3 (es) 2023-02-28
CA3104800A1 (en) 2020-02-06
IL279823B1 (en) 2025-10-01
BR112021001237A2 (pt) 2021-04-27
LT3830132T (lt) 2023-02-10
WO2020025564A1 (en) 2020-02-06
CN112533956B (zh) 2025-05-06
SG11202100607RA (en) 2021-02-25
RS63943B1 (sr) 2023-02-28
JP7586399B2 (ja) 2024-11-19
CL2021000146A1 (es) 2021-07-30
FI3830132T3 (fi) 2023-01-13
HRP20230115T1 (hr) 2023-06-09

Similar Documents

Publication Publication Date Title
AR115288A1 (es) Anticuerpos humanizados contra el psma
MX2021004808A (es) Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos.
AR119295A1 (es) Moléculas de unión a antígeno ligantes de cea
CO2020013089A2 (es) Anticuerpos contra mica y/o micb y sus usos
CL2024001473A1 (es) Conjugados de fármacos y anticuerpos anti-ccr7
MX2021002970A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor.
PE20201341A1 (es) Anticuerpos de union a gprc5d
DOP2021000101A (es) Anticuerpos humanizados contra c-kit
AR107442A1 (es) Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer
PA8849001A1 (es) Anticuerpos de c-met
CO2017001191A2 (es) Conjugados de fármacos con anticuerpos anti-cdh6
PE20171556A1 (es) Agentes de union a cd123 y usos de estos
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
MX2015013203A (es) Conjugados de anticuerpo - farmaco.
MX2020006585A (es) Anticuerpos que se unen a ctla-4 y usos de los mismos.
MX2018005061A (es) Compuestos de interacción con glicanos y métodos de uso.
MX2017006167A (es) Compuestos que interactúan con glicanos y métodos de uso.
CL2019002735A1 (es) Anticuerpos que se unen a steap-1.
BR112015027309A2 (pt) anticorpo, composição, método de tratamento e uso de um anticorpo
BR112016024214A2 (pt) anticorpos antigênicos anti-tf humanizados
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
JOP20190103B1 (ar) شدفة Fab جديدة لجسم مضاد ضد MUC1 بشري
MX2025000437A (es) Inmunoconjugados de epcam y usos de estos
AR114129A1 (es) ANTICUERPOS TERAPÉUTICOS DIRIGIDOS CONTRA sPLA2-GIB Y SUS USOS
MX2018000135A (es) Terapia combinada con un conjugado de farmaco y anticuerpo anti receptor 2 de factor de crecimiento epidermico humano (her2) y un inhibidor de linfoma de celulas b2 (bcl-2).